ADCT-241 / ADC Therapeutics - LARVOL DELTA

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028 (PRNewswire) - "ADC Therapeutics SA...announced that it has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $100.0 million private investment in public equity ('PIPE') financing....Gross proceeds from the PIPE financing are anticipated to be approximately $100.0 million before deducting placement agent fees and offering expenses....ADC Therapeutics intends to use the net proceeds from the PIPE to fund multiple catalysts primarily in support of ZYNLONTA clinical development as well as ZYNLONTA commercialization activities, working capital and general corporate purposes....Beyond ZYNLONTA, the Company will advance its preclinical exatecan-based ADC targeting prostate-specific membrane antigen (PSMA) and will discontinue early development efforts for the remaining preclinical programs in solid tumors."

Discontinued • Financing • Diffuse Large B Cell Lymphoma • Solid Tumor

The anticipated catalysts within the cash runway… (PRNewswire) - "PSMA-targeting ADC: Expect to complete IND-enabling activities by end of 2025."

IND • Solid Tumor

Preclinical development of ADCT-241, a novel exatecan-based antibody-drug conjugate targeting PSMA for the treatment of prostate cancer (AACR 2025) - "In summary, ADCT‑241 is a novel, stable PSMA-targeting ADC that mediates potent and specific anti-tumor activity in mouse xenograft models and exhibits an excellent tolerability profile in rats and cynomolgus monkeys. The data presented support future clinical development of ADCT-241 for the treatment of prostate cancer indications."

Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 (PRNewswire) - "ADC Therapeutics SA...announced abstracts detailing multiple preclinical programs have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025....Oral presentation to highlight preclinical investigation of Claudin-6 ADC in ovarian and NSCLC cancer models. Preclinical data for PSMA and ASCT2-targeted ADCs accepted for poster presentations."

Preclinical • Non Small Cell Lung Cancer • Ovarian Cancer • Prostate Cancer